Widely-prescribed class of antibiotics, the fluoroquinolones, need much stronger warnings about the risks for serious adverse events, a US Food and Drug Administration advisory panel said.
Source: Mumbai News
Widely-prescribed antibiotics need stronger warnings: USFDA panel
